Astria Therapeutics Inc Total Liabilities
Astria Therapeutics Inc total liabilities. Based on the latest financial reports, Astria Therapeutics Inc (ATXS) has total liabilities worth $38.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Astria Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Astria Therapeutics Inc (2012–2024)
Total liabilities of Astria Therapeutics Inc from 2012 to 2024. This chart illustrates how Astria Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Astria Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Astria Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DoubleU Games Co Ltd
KO:192080
|
Korea | ₩197.53 Billion |
|
Cangzhou Dahua Co Ltd
SHG:600230
|
China | CN¥1.68 Billion |
|
Shanghai Pudong Road & Bridge Construction Co Ltd
SHG:600284
|
China | CN¥22.52 Billion |
|
JK Paper Limited
NSE:JKPAPER
|
India | Rs-57.86 Billion |
|
Changchun Zhiyuan New Energy Equipment Co. Ltd
SHE:300985
|
China | CN¥1.57 Billion |
|
HELL.UNSP.ADR A1 DL-0001
F:1MO
|
Germany | €2.69 Billion |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
China | CN¥672.43 Million |
|
HDC Holdings Co Ltd
KO:012630
|
Korea | ₩7.76 Trillion |
Liability Composition Analysis (2012–2024)
This chart breaks down Astria Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ATXS total asset value.
Liquidity & Leverage Metrics
Astria Therapeutics Inc Total Liabilities Ratios Explained
Astria Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Astria Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Astria Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Astria Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $23.10 Million | +100.00% |
| 2023-12-31 | $11.55 Million | +22.65% |
| 2022-12-31 | $9.42 Million | +80.99% |
| 2021-12-31 | $5.20 Million | -23.34% |
| 2020-12-31 | $6.79 Million | +12.00% |
| 2019-12-31 | $6.06 Million | +43.36% |
| 2018-12-31 | $4.23 Million | -30.76% |
| 2017-12-31 | $6.11 Million | -45.11% |
| 2016-12-31 | $11.12 Million | -18.99% |
| 2015-12-31 | $13.73 Million | -84.58% |
| 2014-12-31 | $89.02 Million | +7.01% |
| 2013-12-31 | $83.19 Million | +4105823.00% |
| 2012-12-31 | $2.03K | -- |
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more